Cingulate Inc.
$6.03
▲
2.16%
2026-04-21 06:03:00
www.cingulate.com
NCM: CING
Explore Cingulate Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$66.77 M
Current Price
$6.03
52W High / Low
$11.89 / $3.2
Stock P/E
—
Book Value
$0.35
Dividend Yield
—
ROCE
-418.81%
ROE
-4.51%
Face Value
—
EPS
$-4.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
-0.77
Debt / Equity
350.21
Current Ratio
1.16
Quick Ratio
1.16
Forward P/E
-3.96
Price / Sales
—
Enterprise Value
$64.81 M
EV / EBITDA
-3.34
EV / Revenue
—
Rating
Strong Buy
Target Price
$28.7
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 2. | Viridian Therapeutics, Inc. | $14.68 | — | $1.5 B | — | -43.85% | -49.16% | $34.29 / $11.76 | $5.79 |
| 3. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 4. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 5. | Intensity Therapeutics, Inc. | $5.21 | — | $13.46 M | — | -100.14% | -1.57% | $50 / $4.63 | $4.7 |
| 6. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
| 7. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.59 M | -6 M | -4.65 M | -3.71 M | -6.21 M | — |
| Net Profit | -6.27 M | -7.34 M | -4.79 M | -3.8 M | -6.13 M | — |
| EPS in Rs | -0.54 | -0.63 | -0.41 | -0.33 | -0.53 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.94 M | -15.65 M | -22.76 M | -17.5 M |
| Net Profit | -22.45 M | -16.56 M | -23.53 M | -17.68 M |
| EPS in Rs | -1.93 | -1.42 | -2.02 | -1.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.07 M | 14.86 M | 3.49 M | 11.41 M |
| Total Liabilities | 12.56 M | 7.41 M | 10.36 M | 7.52 M |
| Equity | 2.51 M | 7.46 M | -6.87 M | 3.88 M |
| Current Assets | 12.01 M | 12.66 M | 0.58 M | 7.87 M |
| Current Liabilities | 10.31 M | 4.97 M | 10.23 M | 7.01 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -17.25 M | -18.45 M | -15.03 M | -15.88 M |
| Investing CF | -0.16 M | -0.21 M | -0.22 M | -0.15 M |
| Financing CF | 16.15 M | 30.82 M | 9.95 M | 4.9 M |
| Free CF | -17.41 M | -18.66 M | -15.26 M | -16.04 M |
| Capex | -0.16 M | -0.21 M | -0.22 M | -0.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 29.64% | -33.14% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-09 | 1:0.0833333 |
| 2023-11-30 | 1:0.05 |